Samantha Ault
Psychiatric/Mental Health · Zanesville, OHNPI 1831512896
Payments from drug & device makers
Across 195 payments — averaging $30.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corium, LLC$2K
- AbbVie$716
- Alkermes, Inc.$556
- Supernus Pharmaceuticals, Inc.$499
- Axsome Therapeutics, Inc.$431
- Neurocrine Biosciences, Inc.$280
- plus $1K from 11 others
What the payments were for
- Consulting fees$3456%
- Speaking & faculty fees$1,61027%
- Travel & lodging$631%
- Food & beverage$3,91166%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corium, LLC | 23 | $2,448 |
| AbbVie | 55 | $716 |
| Alkermes, Inc. | 16 | $556 |
| Supernus Pharmaceuticals, Inc. | 25 | $499 |
| Axsome Therapeutics, Inc. | 15 | $431 |
| Neurocrine Biosciences, Inc. | 10 | $280 |
| Otsuka America Pharmaceutical, Inc. | 15 | $245 |
| E.r. Squibb & Sons, L.L.C. | 7 | $220 |
| Teva Pharmaceuticals USA, Inc. | 9 | $161 |
| Ironshore Pharmaceuticals Inc. | 5 | $100 |
| Lundbeck LLC | 4 | $92 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $62 |
| Neos Therapeutics, LP | 3 | $47 |
| Johnson & Johnson | 1 | $28 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Tris Pharma Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,935 in reported general payments places this provider in the 90th percentile of 1,808 psychiatric/mental health providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 19 | $31,077 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $9,450 |
| Lamotrigine | 11 | $38 |
| Alprazolam | 13 | $15 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $716 | $31,07719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Zanesville
- Jessica WeigandZanesville$24K
- Anna HarpZanesville$12K
- Deana BatrossZanesville$11K
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Terri PopovitzCincinnati$161K
- Steven MatesDayton$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.